LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 12 of 15: Mean cell count and mean normalized growth rate inhibition values across biological replicate 2. - Dataset (ID:20249)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Normalized Growth Rate Inhibition Value |
---|---|---|---|---|---|---|---|---|---|---|---|
MCF 10A | Radicicol | 0.04 | uM | LJP5 | 72 | hr | 1694 | 9940 | 11103 | 0.8953 | 0.9201 |
MCF 10A | Pictilisib | 0.04 | uM | LJP6 | 72 | hr | 1694 | 9923 | 11217 | 0.8847 | 0.9120 |
MCF 10A | Fedratinib | 1.11 | uM | LJP5 | 72 | hr | 1694 | 9912 | 11103 | 0.8928 | 0.9180 |
MCF 10A | Withaferin A | 0.37 | uM | LJP5 | 72 | hr | 1694 | 9899 | 11103 | 0.8915 | 0.9171 |
MCF 10A | GW843682X | 0.12 | uM | LJP6 | 72 | hr | 1694 | 9876 | 11217 | 0.8806 | 0.9089 |
MCF 10A | GSK 690693 | 3.33 | uM | LJP5 | 72 | hr | 1694 | 9870 | 11103 | 0.8890 | 0.9151 |
MCF 10A | Withaferin A | 0.37 | uM | LJP6 | 72 | hr | 1694 | 9848 | 11217 | 0.8780 | 0.9067 |
MCF 10A | AZD-6482 | 1.11 | uM | LJP5 | 72 | hr | 1694 | 9840 | 11103 | 0.8862 | 0.9128 |
MCF 10A | Crizotinib | 1.11 | uM | LJP5 | 72 | hr | 1694 | 9823 | 11103 | 0.8847 | 0.9116 |
MCF 10A | GSK 690693 | 1.11 | uM | LJP5 | 72 | hr | 1694 | 9787 | 11103 | 0.8815 | 0.9091 |
MCF 10A | XL147 | 3.33 | uM | LJP5 | 72 | hr | 1694 | 9760 | 11103 | 0.8790 | 0.9071 |
MCF 10A | Linsitinib | 0.12 | uM | LJP5 | 72 | hr | 1694 | 9752 | 11103 | 0.8783 | 0.9066 |
MCF 10A | Buparlisib | 0.37 | uM | LJP5 | 72 | hr | 1694 | 9711 | 11103 | 0.8746 | 0.9035 |
MCF 10A | Radicicol | 0.04 | uM | LJP6 | 72 | hr | 1694 | 9703 | 11217 | 0.8651 | 0.8964 |
MCF 10A | AZD 5438 | 0.12 | uM | LJP6 | 72 | hr | 1694 | 9687 | 11217 | 0.8635 | 0.8951 |
MCF 10A | Erlotinib | 0.12 | uM | LJP5 | 72 | hr | 1694 | 9664 | 11103 | 0.8704 | 0.9002 |
MCF 10A | GSK1059615 | 0.12 | uM | LJP6 | 72 | hr | 1694 | 9624 | 11217 | 0.8580 | 0.8908 |
MCF 10A | HG-5-113-01 | 0.12 | uM | LJP5 | 72 | hr | 1694 | 9608 | 11103 | 0.8654 | 0.8957 |
MCF 10A | Lapatinib | 1.11 | uM | LJP6 | 72 | hr | 1694 | 9605 | 11217 | 0.8563 | 0.8894 |
MCF 10A | Dovitinib | 0.12 | uM | LJP5 | 72 | hr | 1694 | 9580 | 11103 | 0.8627 | 0.8938 |
MCF 10A | Alpelisib | 0.37 | uM | LJP5 | 72 | hr | 1694 | 9524 | 11103 | 0.8578 | 0.8900 |
MCF 10A | XMD11-50 | 0.37 | uM | LJP6 | 72 | hr | 1694 | 9518 | 11217 | 0.8486 | 0.8832 |
MCF 10A | PF562271 | 0.04 | uM | LJP6 | 72 | hr | 1694 | 9484 | 11217 | 0.8455 | 0.8806 |
MCF 10A | PIK-93 | 3.33 | uM | LJP5 | 72 | hr | 1694 | 9476 | 11103 | 0.8534 | 0.8864 |
MCF 10A | Nintedanib | 3.33 | uM | LJP6 | 72 | hr | 1694 | 9454 | 11217 | 0.8429 | 0.8785 |